# nature portfolio

Corresponding author(s):	Ryoma Nakao
Last updated by author(s):	Sep 22, 2022

## **Reporting Summary**

Statistics

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement
$\boxtimes$	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
$\boxtimes$	A description of all covariates tested
$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
$\boxtimes$	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
$\boxtimes$	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\bowtie$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated

### Software and code

Policy information about <u>availability of computer code</u>

Data collection No specific software was used for data collection.

Data analysis Graph Pad Prism was used for data analysis.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Provide your data availability statement here.

Human rese	arch parti	cipants	
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.	
Reporting on sex	and gender	No human research was included in the present report.	
Population chara	-	No human research was included in the present report.	
		No human research was included in the present report.	
		No human research was included in the present report.	
Note that full illioning	ation on the appi	oval of the study protocol must also be provided in the manuscript.	
Field-spe	ecific re	enorting	
<u>.</u>		s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
Life sciences		sehavioural & social sciences	
	_	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>	
Life scier	nces sti	udy design	
All studies must dis	sclose on these	points even when the disclosure is negative.	
Sample size	No sample calculation was performed.		
Data exclusions	No data excluded.		
Replication	plication N.A for vaccination of animal experiments for ethical concerns. The reproducibility of data was confirmed by at least 3 independent assays.		
Randomization	N.A.		
Blinding	N.A.		
-			
	6		
Reportin	g tor sp	pecific materials, systems and methods	
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & experimental systems Methods			
n/a Involved in the study n/a Involved in the study			
	Antibodies ChIP-seq		
-1-	Eukaryotic cell lines		
	Palaeontology and archaeology  MRI-based neuroimaging  Animals and other organisms		
Clinical data			
Dual use research of concern			
Antibodies			

Antibodies used

All information of antibodies used in this study was provided in the manuscript.

Validation

Validation for antibodies used in this study was performed by using appropriate controls. Some data regarding validation was provided in the manuscript, e.g., Fig. S1, S2, and S8. The others was not provided, but, those data that support the findings of this study are available upon request from the corresponding author.

## Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals	The information was provided in the manuscript.
Wild animals	No wild animal was used.
Reporting on sex	The information was provided in the manuscript.
Field-collected samples	No field-collected sample was used.
Ethics oversight	In the manuscript, we have described the ethical issue regarding animal experiments with the protocol numbers approved by our institute.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

#### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

## Methodology

Sample preparation	The information was provided in the manuscript.
Instrument	The information was provided in the manuscript.
Software	The information was provided in the manuscript.
Cell population abundance	The information was provided in the manuscript.
Gating strategy	The information was provided in the manuscript.

X Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.